Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Wakayama Substance Supplier Mixed in China-Made Ingredient; MHLW Sees No Safety Concerns
June 23, 2017
-
BUSINESS Development Race Heating Up for HIF-PH Inhibitors, Promising Alternative to ESAs in Renal Anemia Space?
June 22, 2017
-
BUSINESS Amgen Astellas Biopharma Gearing Up for 2020 Takeoff as Stand-Alone Subsidiary
June 20, 2017
-
ORGANIZATION FPMAJ Calls for Maintaining Prices for On-Patent Drugs, Lower Price Reduction Rates in Off-Year Revisions
June 19, 2017
-
BUSINESS Biogen Japan Upbeat on Tecfidera, Near-Approval Nusinersen, Sakigake Boost for Aducanumab
June 19, 2017
-
TRENDS Authorized Generics Solidifying Their Presence in Japan Gx Market
June 16, 2017
-
REGULATORY 1st Generics for 13 APIs to Join NHI Price List on June 16; Micardis, Abilify Face Competition
June 15, 2017
-
REGULATORY (Update) Add’l Eligibility Criteria Proposed for Companies to Get Price Maintenance Premium, Tiered Premiums Eyed: Chuikyo
June 15, 2017
-
REGULATORY Add’l Eligibility Criteria Proposed for Companies to Get Price Maintenance Premium: Chuikyo
June 14, 2017
-
ACADEMIA Japanese Society of Hypertension to Verify Results of SPRINT Study
June 14, 2017
-
ORGANIZATION JGA Appreciates Tweaked Honebuto Text on Generics, 80% Goal Achievable on Production Basis
June 13, 2017
-
REGULATORY Govt’s Regulatory Reform Plan Embraces Review of 14-Day Prescription Limit
June 12, 2017
-
REGULATORY Japan Cabinet Adopts 2017 Honebuto Policy
June 12, 2017
-
ORGANIZATION JMA’s Nakagawa Questions Price Difference for LLPs and AGs, Negative about PhRMA Pitch for AWP Alternatives
June 9, 2017
-
BUSINESS FDA Accepts Sawai’s ANDA for Tecfidera Generic
June 8, 2017
-
BUSINESS Pfizer Boosting Global Oncology Footprint with Diverse Portfolio: SVP
June 7, 2017
-
BUSINESS Discontinuation of Development Continues for Novel Diabetes Drugs, Including Daiichi Sankyo’s GPR119 Agonist
June 6, 2017
-
BUSINESS AbbVie to Seek Indication Expansions for Humira, Competing with Biosimilars on the Strength of Original Product’s Reliability
June 5, 2017
-
REGULATORY Draft Honebuto Policy OK’ed by CEFP, Says Distinguish “Me Too” Drugs from Pioneering Meds
June 5, 2017
-
REGULATORY 4 Eligibility Criteria Presented for Conditional Early Approval System
June 2, 2017
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…